Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

@inproceedings{Dreyling2017PhaseIS,
  title={Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma},
  author={Martin H. Dreyling and Franck Morschhauser and Kamal Bouabdallah and Dominique Bron and David C. Cunningham and Sarit E. Assouline and G. Verhoef and Kim M. Linton and Catherine Thi{\'e}blemont and Umberto Vitolo and Florian Hiemeyer and Marius Giurescu and Jose E Garcia-Vargas and Igor Gorbatchevsky and Linshan Liu and Karl Koechert and Claudia Pe{\~n}a and M. Neves and Barrett H. Childs and Pier Luigi Zinzani},
  booktitle={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2017}
}
Background Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. Patients and methods This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. Results Thirty-three patients with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Drug Administration

  • U. S. Foo
  • FDA alerts healthcare professionals about…
  • 2017
2 Excerpts

Similar Papers

Loading similar papers…